INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing innovative treatments for rare diseases [3]. Allegations and Impact - The FDA authorized Soleno's VYKAT XR (diazoxide choline) on March 26, 2025, for treating hyperphagia in patients aged four years and older with Prader-Willi syndrome [4]. - By November 4, 2025, Soleno reported an 8% discontinuation rate of the drug due to side effects and indicated that a short-seller report from mid-August had delayed the drug's rollout [4]. - Following these developments, Soleno's stock price experienced a decline of over 26% [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws related to Soleno, stemming from allegations of providing misleading business information to investors [1].